Just had a thought - maybe @Phaedrus is the go to here.
We have been talking sales - 1 patient - 1 and a half patients is equal to x amount of sales revenue etc.
Mesoblast has stated we have over 200 million of the US population now with insurance coverage for Ryoncil.
As paediatric SR aGvHD was an unmet need - there is no alternative therapy.
What is the law?
What is the law that governs insurers having to fulfil their policy commitments?
I'm sure policies have caps on expenditure on an annual basis - maybe I'm opening a can of worms- but if Mesoblast says they have approved coverage then I would suggest it is for the full course.
What am I banging on about ?
We should not be talking about trying to sell a product -Rather we are meeting a need.
At present we have teams in the field onboarding all the transplant centres in the US and bringing them up to speed on administering Ryoncil to critically ill patients.
If the insurer is required by law to pay for the therapy then market penetration will be swift and July 31 may provide more of an upside than anyone has predicted.
Anyhoo - positive musings - off to bed now
Needs not sales - I like it
Reg
MSB Price at posting:
$1.66 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)